Database Update: Pharmaceutical Drug Import to Russia (June 2017)
Between January and June 2017, Russia imported 238.5 bln RUB worth of ready-made drugs (free circulation prices), which is 8.1% higher in monetary terms. Due to the poor June performance, the long-term dynamics are -1%. The in-bulk import has been falling down for four months, with 42.7 bln RUB, which is 25.5% lower than that of 2016.
In physical terms, Russia import 946.1 mln units of ready-made drugs, which is 6% higher than that of 2016. In June, the increase in the import was only 1% if calculated in units due to the decrease in consumer packages. If calculated in minimum dosage units, (MDU), the import of ready-made products has fallen by 5% (to 17.1 bln MDUs.) While the in-bulk import has grown by 9.2% in physical terms, it amounts to 2.2 bln MDUs, that is why the total import dynamics are -1%.
Among the 10 largest importers of ready-made drugs, GSK has the best progress in monetary terms (+60%), while TEVA has the worst dynamics (-27%). Among the largest importers of in-bulk products, Octapharma has the best progress (+202%), while Roche has the worst dynamics (-66%).
Read more about pharmaceutical drug import to Russia (May performance) here: http://rncph.com/news/16_06_2017
Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance, RUB (January 2016 – June 2017)